CU20140003A7 - Conjugado que comprende eritropoyetina y una estructura polimérica ramificada - Google Patents

Conjugado que comprende eritropoyetina y una estructura polimérica ramificada

Info

Publication number
CU20140003A7
CU20140003A7 CUP2014000003A CU20140003A CU20140003A7 CU 20140003 A7 CU20140003 A7 CU 20140003A7 CU P2014000003 A CUP2014000003 A CU P2014000003A CU 20140003 A CU20140003 A CU 20140003A CU 20140003 A7 CU20140003 A7 CU 20140003A7
Authority
CU
Cuba
Prior art keywords
conjugate
kda
mpeg
erythropoyetin
understanding
Prior art date
Application number
CUP2014000003A
Other languages
English (en)
Inventor
Meireles Rolando Páez
González Daniel Enrique Amaro
Odio Fidel Raúl Castro
Valdés Yenisel Hernández
Estrada Gladys Amalia Ruiz
Original Assignee
Ct De Inmunología Molecular Biofarmacuba
Ct De Ingeniería Genética Y Biotecnología Biocubafarma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct De Inmunología Molecular Biofarmacuba, Ct De Ingeniería Genética Y Biotecnología Biocubafarma filed Critical Ct De Inmunología Molecular Biofarmacuba
Priority to CUP2014000003A priority Critical patent/CU20140003A7/es
Priority to TW104100285A priority patent/TWI561245B/zh
Priority to EP15705897.5A priority patent/EP3093024A1/en
Priority to ARP150100036A priority patent/AR099045A1/es
Priority to EA201691386A priority patent/EA201691386A1/ru
Priority to MX2016008928A priority patent/MX2016008928A/es
Priority to SG11201604984TA priority patent/SG11201604984TA/en
Priority to PCT/CU2015/000001 priority patent/WO2015104008A1/es
Priority to AU2015205774A priority patent/AU2015205774B2/en
Priority to CN201580004018.1A priority patent/CN106163541A/zh
Priority to JP2016545283A priority patent/JP6367952B2/ja
Priority to CA2935306A priority patent/CA2935306A1/en
Priority to US15/108,862 priority patent/US20160317674A1/en
Priority to KR1020167018696A priority patent/KR20160105811A/ko
Priority to NZ722092A priority patent/NZ722092A/en
Publication of CU20140003A7 publication Critical patent/CU20140003A7/es
Priority to IL246526A priority patent/IL246526A0/en
Priority to ZA2016/04636A priority patent/ZA201604636B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polyethers (AREA)

Abstract

La presente invención revela un conjugado que comprende eritropoyetina (EPO) y una estructura polimérica ramificada asimétrica que comprende dos ramas de monometoxipolietilenglicol (mPEG) donde la masa molecular de una de estas ramas de mPEG está entre 10 kDa y 23 kDa, y la masa molecular de la otra rama de mPEG está entre 17 kDa y 23kDa, así como las composiciones farmacéuticas que lo contienen. La invención también provee un método para la obtención de EPO peguilada que se caracteriza porque dicha proteína se conjuga a una estructura polimérica ramificada asimétrica, con dos ramas de mPEG que poseen las masas moleculares antes descritas.
CUP2014000003A 2014-01-08 2014-01-08 Conjugado que comprende eritropoyetina y una estructura polimérica ramificada CU20140003A7 (es)

Priority Applications (17)

Application Number Priority Date Filing Date Title
CUP2014000003A CU20140003A7 (es) 2014-01-08 2014-01-08 Conjugado que comprende eritropoyetina y una estructura polimérica ramificada
TW104100285A TWI561245B (en) 2014-01-08 2015-01-06 Conjugate comprising erythropoietin and a branched polymeric structure
PCT/CU2015/000001 WO2015104008A1 (es) 2014-01-08 2015-01-08 Conjugado que comprende eritropoyetina y una estructura polimérica ramificada
CN201580004018.1A CN106163541A (zh) 2014-01-08 2015-01-08 包含促红细胞生成素和支化聚合物结构的缀合物
EA201691386A EA201691386A1 (ru) 2014-01-08 2015-01-08 Конъюгат, включающий эритропоэтин и разветвленную полимерную структуру
MX2016008928A MX2016008928A (es) 2014-01-08 2015-01-08 Conjugado que comprende eritropoyetina y una estructura polimerica ramificada.
SG11201604984TA SG11201604984TA (en) 2014-01-08 2015-01-08 Conjugate comprising erythropoietin and a branched polymer structure
EP15705897.5A EP3093024A1 (en) 2014-01-08 2015-01-08 Conjugate comprising erythropoietin and a branched polymer structure
AU2015205774A AU2015205774B2 (en) 2014-01-08 2015-01-08 Conjugate comprising erythropoietin and a branched polymer structure
ARP150100036A AR099045A1 (es) 2014-01-08 2015-01-08 Conjugado que comprende eritropoyetina y una estructura polimérica ramificada
JP2016545283A JP6367952B2 (ja) 2014-01-08 2015-01-08 エリスロポエチンおよび分枝ポリマー構造を含む複合体
CA2935306A CA2935306A1 (en) 2014-01-08 2015-01-08 Conjugate comprising erythropoietin and a branched polymer structure
US15/108,862 US20160317674A1 (en) 2014-01-08 2015-01-08 Conjugate comprising erythropoietin and a branched polymer structure
KR1020167018696A KR20160105811A (ko) 2014-01-08 2015-01-08 에리트로포이에틴을 포함하는 컨쥬게이트 및 분지형 폴리머 구조
NZ722092A NZ722092A (en) 2014-01-08 2015-01-08 Conjugate comprising erythropoietin and a branched polymer structure
IL246526A IL246526A0 (en) 2014-01-08 2016-06-29 A bracelet containing erythropoietin and a branched polymer structure
ZA2016/04636A ZA201604636B (en) 2014-01-08 2016-07-07 Conjugate comprising erythropoietin and a branched polymeric structure

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CUP2014000003A CU20140003A7 (es) 2014-01-08 2014-01-08 Conjugado que comprende eritropoyetina y una estructura polimérica ramificada

Publications (1)

Publication Number Publication Date
CU20140003A7 true CU20140003A7 (es) 2015-08-27

Family

ID=52573994

Family Applications (1)

Application Number Title Priority Date Filing Date
CUP2014000003A CU20140003A7 (es) 2014-01-08 2014-01-08 Conjugado que comprende eritropoyetina y una estructura polimérica ramificada

Country Status (17)

Country Link
US (1) US20160317674A1 (es)
EP (1) EP3093024A1 (es)
JP (1) JP6367952B2 (es)
KR (1) KR20160105811A (es)
CN (1) CN106163541A (es)
AR (1) AR099045A1 (es)
AU (1) AU2015205774B2 (es)
CA (1) CA2935306A1 (es)
CU (1) CU20140003A7 (es)
EA (1) EA201691386A1 (es)
IL (1) IL246526A0 (es)
MX (1) MX2016008928A (es)
NZ (1) NZ722092A (es)
SG (1) SG11201604984TA (es)
TW (1) TWI561245B (es)
WO (1) WO2015104008A1 (es)
ZA (1) ZA201604636B (es)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6514533B1 (en) 1992-06-11 2003-02-04 Alkermas Controlled Therapeutics, Inc. Device for the sustained release of aggregation-stabilized, biologically active agent
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
JP3967594B2 (ja) 2000-05-15 2007-08-29 エフ．ホフマン−ラ ロシュ アーゲー 新しい薬剤組成物
CN1176137C (zh) * 2002-01-15 2004-11-17 泛亚生物技术有限公司 多臂树杈型功能化聚乙二醇制备方法及它在药物中的应用
US20040136952A1 (en) * 2002-12-26 2004-07-15 Mountain View Pharmaceuticals, Inc. Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
WO2006061853A2 (en) * 2004-12-10 2006-06-15 Serum Institute Of India Limited Novel erythropoietic compounds and a process for producing erythropoietic compounds
CU23556A1 (es) * 2005-11-30 2010-07-20 Ct Ingenieria Genetica Biotech Estructura polimérica semejante a dendrímero para la obtención de conjugados de interés farmacéutico
PT2054074E (pt) * 2006-08-04 2014-11-07 Prolong Pharmaceuticals Llc Eritropoietina modificada
US8188222B2 (en) * 2006-11-08 2012-05-29 Nippon Kayaku Kabushiki Kaisha High molecular weight derivative of nucleic acid antimetabolite
CN101376676B (zh) * 2008-10-09 2012-04-25 天津派格生物技术有限公司 聚乙二醇化红细胞生成素蛋白长效制剂

Also Published As

Publication number Publication date
ZA201604636B (en) 2018-05-30
JP2017506619A (ja) 2017-03-09
IL246526A0 (en) 2016-08-31
NZ722092A (en) 2017-11-24
AR099045A1 (es) 2016-06-22
KR20160105811A (ko) 2016-09-07
AU2015205774B2 (en) 2017-11-30
SG11201604984TA (en) 2016-07-28
CA2935306A1 (en) 2015-07-16
WO2015104008A1 (es) 2015-07-16
US20160317674A1 (en) 2016-11-03
TWI561245B (en) 2016-12-11
WO2015104008A8 (es) 2016-08-25
TW201538168A (zh) 2015-10-16
MX2016008928A (es) 2016-10-04
EP3093024A1 (en) 2016-11-16
AU2015205774A1 (en) 2016-07-28
CN106163541A (zh) 2016-11-23
EA201691386A1 (ru) 2016-11-30
JP6367952B2 (ja) 2018-08-01

Similar Documents

Publication Publication Date Title
IL266693A (en) Conjugated biological compounds, pharmaceutical preparations and methods
MX367851B (es) Conjugados de proteína-polímero-fármaco.
CY1121949T1 (el) Φαρμακοτεχνικες μορφες συζευγματος anti-egfr αντισωματος-φαρμακου
EP3562510A4 (en) BRANCHED PEG MOLECULES AND ASSOCIATED COMPOSITIONS AND PROCEDURES
MX2016004659A (es) Conjugados proteina-polimero-farmaco.
CY1122329T1 (el) Anti-siglec-8 αντισωματα και μeθοδοι χρhσεως αυτων
WO2015153753A3 (en) Conjugates of an il-15 moiety and a polymer
CO2019009258A2 (es) Administración rápida y controlada de composiciones con efectos séquito restaurados
WO2017003639A3 (en) Free-standing non-fouling polymers, their compositions, and related monomers
UY34617A (es) Composiciones veterinarias orales parasiticidas que comprenden agentes activos de acción sistémica, métodos y usos de las mismas
WO2014179629A8 (en) Compositions and methods
WO2016060996A3 (en) Interleukin-15 compositions and uses thereof
CO2020005349A2 (es) Composiciones de hierbas con mejor biodisponibilidad
DK3380529T3 (da) Aktiverede pektinholdige biomassesammensætninger, produkter og fremgangsmåder til fremstilling heraf
PH12019501199A1 (en) Calcium lactate compositions and methods of use
BR112017021499A2 (pt) composição, produto agrícola de múltiplas embalagens e método para aumentar a capacidade de absorção de água de um polímero superabsorvente
BR112017020141A2 (pt) produção de uma espuma de pmma usando agentes de reticulação, reguladores e agentes de expansão.
MA47601A (fr) Faible viscosité, formulations d'évolocumab à haute concentration et leurs procédés de préparation
UY35545A (es) Composiciones y procedimientos para inducir tolerancia inmunitaria a las proteínas factores de coag ulación
BR112016010072A8 (pt) conjugado, composição farmacêutica, usos do conjugado ou da composição farmacêutica, e de polissacarídeo de vi fragmentado, e, método para a fabricação de um conjugado
DK3478310T3 (da) Sammensætninger, som er anvendelige inden for forebyggelsen og/eller behandlingen af osteoartikulær inflammation og smerte samt bruskskade
WO2017075171A3 (en) Pamam dendrimer based cest imaging agents and uses thereof
BR112015027832A2 (pt) copolímeros estatísticos livres de açucar feitos pelo menos três monômeros
CU20140003A7 (es) Conjugado que comprende eritropoyetina y una estructura polimérica ramificada
CY1122568T1 (el) Διαχειριση της οστεοπορωσης me hmw peg